These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 11048998)

  • 1. The effect of Daclizumab in a high-risk renal transplant population.
    Meier-Kriesche HU; Kaza H; Palekar SS; Friedman GS; Mulgaonkar SP; Ojo AO; Kaplan B
    Clin Transplant; 2000 Oct; 14(5):509-13. PubMed ID: 11048998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study.
    Woodroffe R; Yao GL; Meads C; Bayliss S; Ready A; Raftery J; Taylor RS
    Health Technol Assess; 2005 May; 9(21):1-179, iii-iv. PubMed ID: 15899149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Daclizumab in an African-American and Hispanic renal transplant population.
    Meier-Kriesche HU; Palenkar SS; Friedman GS; Mulgaonkar SP; Goldblat MV; Kaplan B
    Transpl Int; 2000; 13(2):142-5. PubMed ID: 10836651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicenter, open-label, comparative trial of two daclizumab dosing strategies vs. no antibody induction in combination with tacrolimus, mycophenolate mofetil, and steroids for the prevention of acute rejection in simultaneous kidney-pancreas transplant recipients: interim analysis.
    Stratta RJ; Alloway RR; Hodge E; Lo A;
    Clin Transplant; 2002 Feb; 16(1):60-8. PubMed ID: 11982617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of daclizumab, tacrolimus and mycophenolate mofetil in african-american and Hispanic first renal transplant recipients.
    Ciancio G; Burke GW; Suzart K; Mattiazzi A; Vaidya A; Roth D; Kupin W; Rosen A; Johnson N; Miller J
    Am J Transplant; 2003 Aug; 3(8):1010-6. PubMed ID: 12859538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Avoidance of cyclosporine in renal transplantation: effects of daclizumab, mycophenolate mofetil, and steroids.
    Tran HTB; Acharya MK; McKay DB; Sayegh MH; Carpenter CB; Auchincloss H; Kirkman RL; Milford EL
    J Am Soc Nephrol; 2000 Oct; 11(10):1903-1909. PubMed ID: 11004222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in renal transplantation at 24 months of follow-up.
    Ciancio G; Burke GW; Gaynor JJ; Roth D; Kupin W; Rosen A; Cordovilla T; Tueros L; Herrada E; Miller J
    Clin Transplant; 2008; 22(2):200-10. PubMed ID: 18339140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study.
    Ekberg H; Grinyó J; Nashan B; Vanrenterghem Y; Vincenti F; Voulgari A; Truman M; Nasmyth-Miller C; Rashford M
    Am J Transplant; 2007 Mar; 7(3):560-70. PubMed ID: 17229079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Limited dose monoclonal IL-2R antibody induction protocol after primary kidney transplantation.
    Ahsan N; Holman MJ; Jarowenko MV; Razzaque MS; Yang HC
    Am J Transplant; 2002 Jul; 2(6):568-73. PubMed ID: 12118902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Daclizumab induction, tacrolimus, mycophenolate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipients.
    Ciancio G; Burke GW; Suzart K; Roth D; Kupin W; Rosen A; Olson L; Esquenazi V; Miller J
    Transplantation; 2002 Apr; 73(7):1100-6. PubMed ID: 11965039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Daclizumab: a review of its use in the prevention of acute rejection in renal transplant recipients.
    Wiseman LR; Faulds D
    Drugs; 1999 Dec; 58(6):1029-42. PubMed ID: 10651389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of daclizumab and mycophenolate mofetil with cyclosporine and steroids in renal transplantation.
    Pescovitz MD; Bumgardner G; Gaston RS; Kirkman RL; Light S; Patel IH; Nieforth K; Vincenti F
    Clin Transplant; 2003 Dec; 17(6):511-7. PubMed ID: 14756266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of daclizumab, low-dose cyclosporine, mycophenolate mofetil and steroids on renal function after kidney transplantation.
    Fangmann J; Arns W; Marti HP; Hauss J; Ketteler M; Beckurts T; Boesmueller C; Pohanka E; Martin PY; Gerhardt M; Farese S; Neumayer HH; Floege J; Gurr C; Budde K;
    Nephrol Dial Transplant; 2010 Jan; 25(1):283-92. PubMed ID: 19773417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and cardiovascular safety of daclizumab, mycophenolate mofetil, tacrolimus, and early steroid withdrawal in renal transplant recipients: a multicenter, prospective, pilot trial.
    Abramowicz D; Vanrenterghem Y; Squifflet JP; Kuypers D; Mourad M; Meurisse M; Wissing M
    Clin Transplant; 2005 Aug; 19(4):475-82. PubMed ID: 16008591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group.
    Nashan B; Light S; Hardie IR; Lin A; Johnson JR
    Transplantation; 1999 Jan; 67(1):110-5. PubMed ID: 9921806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mycophenolate mofetil reduces the risk of acute rejection less in African-American than in Caucasian kidney recipients.
    Schweitzer EJ; Yoon S; Fink J; Wiland A; Anderson L; Kuo PC; Lim JW; Johnson LB; Farney AC; Weir MR; Bartlett ST
    Transplantation; 1998 Jan; 65(2):242-8. PubMed ID: 9458022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation.
    Bumgardner GL; Hardie I; Johnson RW; Lin A; Nashan B; Pescovitz MD; Ramos E; Vincenti F;
    Transplantation; 2001 Sep; 72(5):839-45. PubMed ID: 11571447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of early acute rejection with daclizumab and triple immunosuppression in cadaveric renal allograft recipients.
    Kandus A; Grego K; Bren AF
    Ther Apher Dial; 2005 Jun; 9(3):262-4. PubMed ID: 15967003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experience with daclizumab in liver transplantation: renal transplant dosing without calcineurin inhibitors is insufficient to prevent acute rejection in liver transplantation.
    Hirose R; Roberts JP; Quan D; Osorio RW; Freise C; Ascher NL; Stock PG
    Transplantation; 2000 Jan; 69(2):307-11. PubMed ID: 10670644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two doses of daclizumab in conjunction with low-dose cyclosporine, mycophenolate mofetil and steroids resulted in a low incidence of acute rejection after renal transplantation.
    Ekberg H; Persson NH; Källen R; Gül-Baykurt N
    Scand J Immunol; 2003 Dec; 58(6):670-7. PubMed ID: 14636424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.